Search
00
GBAF Logo
trophy
Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking & Finance Review®

Global Banking & Finance Review® - Subscribe to our newsletter

Company

    GBAF Logo
    • About Us
    • Profile
    • Privacy & Cookie Policy
    • Terms of Use
    • Contact Us
    • Advertising
    • Submit Post
    • Latest News
    • Research Reports
    • Press Release
    • Awards▾
      • About the Awards
      • Awards TimeTable
      • Submit Nominations
      • Testimonials
      • Media Room
      • Award Winners
      • FAQ
    • Magazines▾
      • Global Banking & Finance Review Magazine Issue 79
      • Global Banking & Finance Review Magazine Issue 78
      • Global Banking & Finance Review Magazine Issue 77
      • Global Banking & Finance Review Magazine Issue 76
      • Global Banking & Finance Review Magazine Issue 75
      • Global Banking & Finance Review Magazine Issue 73
      • Global Banking & Finance Review Magazine Issue 71
      • Global Banking & Finance Review Magazine Issue 70
      • Global Banking & Finance Review Magazine Issue 69
      • Global Banking & Finance Review Magazine Issue 66
    Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

    Global Banking & Finance Review® is a leading financial portal and online magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management.
    Copyright © 2010-2026 GBAF Publications Ltd - All Rights Reserved. | Sitemap | Tags | Developed By eCorpIT

    Editorial & Advertiser disclosure

    Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    Home > Top Stories > AstraZeneca vaccine faces resistance in Europe after health workers suffer side-effects
    Top Stories

    AstraZeneca vaccine faces resistance in Europe after health workers suffer side-effects

    Published by linker 5

    Posted on February 18, 2021

    5 min read

    Last updated: January 21, 2026

    The image shows healthcare professionals giving the AstraZeneca COVID-19 vaccine, highlighting the resistance faced in Europe due to reported side-effects. This reflects the growing concerns among health workers and the impact on healthcare services.
    Healthcare workers administering AstraZeneca COVID-19 vaccine amidst European resistance - Global Banking & Finance Review
    Why waste money on news and opinion when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe

    By Caroline Pailliez and Johan Ahlander

    PARIS (Reuters) – Health authorities in some European countries are facing resistance to AstraZeneca’s COVID-19 vaccine after side-effects led hospital staff and other front-line workers to call in sick, putting extra strain on already-stretched services.

    Such symptoms, as reported in clinical trials for the AstraZeneca shot, can include a high temperature or headache and are a normal sign that the body is generating an immune response. They usually fade within a day or so.

    The other shots approved in Europe, developed by Pfizer and Moderna, have been linked to similar temporary side-effects, including fever and fatigue.

    But with the AstraZeneca shot the latest to be rolled out, health authorities in France have issued guidance to stagger giving the shot, two regions in Sweden paused vaccinations, and in Germany some essential workers are refusing it.

    A spokesman for AstraZeneca said: “Currently, the reactions reported are as we would expect based on the evidence gathered from our clinical trial programme.”

    People receiving the vaccine are closely monitored through routine pharmacovigilance activities, the Anglo-Swedish drug maker said, adding that it was continuing to keep a close eye on the situation.

    “There have been no confirmed serious adverse events,” the spokesman said.

    ‘MORE SIDE-EFFECTS’

    In France, which started administering the AstraZeneca shot on Feb. 6, staff at a hospital in Normandy experienced stronger side-effects than seen with the alternative vaccine from Pfizer and German partner BioNTech.

    “AstraZeneca caused more side-effects than the Pfizer vaccine,” said Melanie Cotigny, communications manager at Saint-Lo hospital in Normandy.

    “Between 10% and 15% of those vaccinated may have side-effects from this vaccination, but it is only a feverish state, fevers, nausea and within 12 hours it goes away.”

    Following similar reports from other hospitals, the French medicines safety agency said on Feb. 11 that such side-effects were “known and described” but should be subject to surveillance with regard to their intensity.

    It also issued guidance to stagger vaccinations of front-line staff working together in teams to minimise the risk of disruption to operations.

    The agency put out the advice after receiving 149 alerts of often strong flu-like side-effects from the AstraZeneca vaccine. During this period a total of 10,000 people received the shot nationwide.

    Some U.S. hospitals and other organisations with front-line staff adopted a similar strategy when the country’s vaccination programme started in December. The United States is administering shots from Pfizer/BioNTech and Moderna.

    In Britain, home to the AstraZeneca vaccine developed at Oxford University, the policy has been to make vaccinations readily available to hospital staff. As many work shifts, that naturally spaces out the process.

    The issues in France highlight how some doctors and hospitals are still learning how best to administer vaccines as governments race to tame the pandemic and get shots in arms as quickly as possible.

    It’s also the latest setback for the French vaccination campaign which has been criticised for a slow start. Last week, the government said just over 3% of the population had received their first dose.

    In Sweden, two of 21 healthcare regions paused vaccinations of workers last week after a quarter called in sick after getting the AstraZeneca shot.

    The Sormland and Gavleborg regions said that around 100 out of 400 people vaccinated had reported fever or fever-like symptoms. Most cases were mild and in line with previously reported side-effects.

    Both regions said they would resume vaccinations, and the Swedish Medical Products Agency saw no reason to change its vaccination guidelines.

    NO SHOWS

    AstraZeneca’s vector-based vaccine is the third to win regulatory approval in the European Union.

    As part of the European Medicines Agency’s positive recommendation on Jan. 29, the watchdog concluded it was about 60% effective, compared to more than 90% for the vaccines from Pfizer/BioNTech and Moderna.

    It also deemed the product safe to use and it will monitor reports of side-effects as a matter of routine.

    In Germany, Health Minister Jens Spahn responded on Wednesday to reports that essential workers were reluctant to receive the AstraZeneca shot after some experienced strong side-effects, saying it was both safe and effective.

    “I would be vaccinated with it immediately,” Spahn told reporters.

    Like most European countries, German states typically do not offer people a choice of which vaccine they will get, leading in some cases to people not turning up to appointments to get the AstraZeneca vaccine.

    Germany has taken delivery of 737,000 doses from AstraZeneca but only administered 107,000, according to figures from the health ministry and the Robert Koch Institute that leads its pandemic response.

    “This vaccine is an excellent way to prevent serious COVID disease,” said the health ministry in the eastern state of Saxony. “Still, we note that there are still vacant vaccination dates for AstraZeneca.

    “From our point of view, it is wrong that this vaccine is available but not being used,” it said, adding that it was reallocating spare shots to teachers and public health workers.

    (Caroline Pailliez reported from Paris, Johan Ahlander from Stockholm; Additional reporting by Caroline Copley in Berlin, Ludwig Burger in Frankfurt, Richard Lough in Paris and Paul Sandle in London; Writing by Douglas Busvine; Editing by Josephine Mason and Nick Macfie)

     

    More from Top Stories

    Explore more articles in the Top Stories category

    Image for Lessons From the Ring and the Deal Table: How Boxing Shapes Steven Nigro’s Approach to Banking and Life
    Lessons From the Ring and the Deal Table: How Boxing Shapes Steven Nigro’s Approach to Banking and Life
    Image for Joe Kiani in 2025: Capital, Conviction, and a Focused Return to Innovation
    Joe Kiani in 2025: Capital, Conviction, and a Focused Return to Innovation
    Image for Marco Robinson – CLOSE THE DEAL AND SUDDENLY GROW RICH
    Marco Robinson – CLOSE THE DEAL AND SUDDENLY GROW RICH
    Image for Digital Tracing: Turning a regulatory obligation into a commercial advantage
    Digital Tracing: Turning a regulatory obligation into a commercial advantage
    Image for Exploring the Role of Blockchain and the Bitcoin Price Today in Education
    Exploring the Role of Blockchain and the Bitcoin Price Today in Education
    Image for Inside the World’s First Collection Industry Conglomerate: PCA Global’s Platform Strategy
    Inside the World’s First Collection Industry Conglomerate: PCA Global’s Platform Strategy
    Image for Chase Buchanan Private Wealth Management Highlights Key Autumn 2025 Budget Takeaways for Expats
    Chase Buchanan Private Wealth Management Highlights Key Autumn 2025 Budget Takeaways for Expats
    Image for PayLaju Strengthens Its Position as Malaysia’s Trusted Interest-Free Sharia-Compliant Loan Provider
    PayLaju Strengthens Its Position as Malaysia’s Trusted Interest-Free Sharia-Compliant Loan Provider
    Image for A Notable Update for Employee Health Benefits:
    A Notable Update for Employee Health Benefits:
    Image for Creating Equity Between Walls: How Mohak Chauhan is Using Engineering, Finance, and Community Vision to Reengineer Affordable Housing
    Creating Equity Between Walls: How Mohak Chauhan is Using Engineering, Finance, and Community Vision to Reengineer Affordable Housing
    Image for Upcoming Book on Real Estate Investing: Harvard Grace Capital Founder Stewart Heath’s Puts Lessons in Print
    Upcoming Book on Real Estate Investing: Harvard Grace Capital Founder Stewart Heath’s Puts Lessons in Print
    Image for ELECTIVA MARKS A LANDMARK FIRST YEAR WITH MAJOR SENIOR APPOINTMENTS AND EXPANSION MILESTONES
    ELECTIVA MARKS A LANDMARK FIRST YEAR WITH MAJOR SENIOR APPOINTMENTS AND EXPANSION MILESTONES
    View All Top Stories Posts
    Previous Top Stories PostSunak reaffirms goal of ‘sustainable’ borrowing
    Next Top Stories PostEU puts WTO at centre of greener trade reform push